PTC Inc. (PTC) is scheduled to report second-quarter fiscal 2025 results on April 30, 2025, after market close.For the quarter, PTC anticipates revenues between $590 million and $620 million. Non-GAAP EPS is expected in the range of $1.30 to $1.50. The Zacks Consensus Estimate for revenues is pegged at $608.3 million, indicating an increase of 0.9% from the year-ago reported number. The consensus estimate for earnings is $1.38 per share, down 5.5% from a year ago, unchanged in the past seven days.The compan ...

- Label includes full spectrum of PKU patients -- European launch preparations underway -WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the marketing authorization application for Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The opinion includes a broad label inclusive ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider PTC Inc. (PTC) . This company, which is in the Zacks Computer - Software industry, shows potential for another earnings beat.This product development software maker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 14.29 ...

WARREN, N.J., April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, May 6, at 4:30 p.m. ET.To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in for the conference call 15 minutes prior to the start of ...

PTC Inc. (PTC) recently unveiled two powerful additions to its Onshape platform — Onshape AI Advisor and Onshape Government. These innovative offerings highlight PTC's commitment to empowering engineers, designers and regulated organizations with powerful tools to streamline product development, enhance productivity and ensure regulatory compliance. By fusing generative artificial intelligence (AI) and compliance-grade infrastructure into its cloud-native computer-aided design (CAD) and product data managem ...

New AI-powered assistant offers designers step-by-step guidance and recommendations during design process Onshape Government delivers cloud-native CAD and PDM to aerospace and defense companies with ITAR and EAR compliance requirements BOSTON, April 15, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced two new offerings from its cloud-native Onshape® computer-aided design (CAD) and product data management (PDM) platform: Onshape AI Advisor, an intelligent, generative AI-powered assistant that enables ...

BOSTON, April 9, 2025 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2025 second quarter results on Wednesday, April 30th after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, April 30th at 5pm Eastern Time. The earnings press release, accompanying earnings presentation, and financial data tables will be accessible prior to the conference call and webcast on the Investor Relations section of the Company's website at PTC I ...

BOSTON, April 2, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the acquisition of IncQuery Group. IncQuery Group offers application lifecycle management (ALM) and systems engineering development and consultancy services to global manufacturers and product companies. IncQuery Group helps simplify the product development process by connecting hardware and software engineering systems and enables better collaboration across development teams and more efficient management of product data. The acquisiti ...

文章核心观点 - PTC公司推出Codebeamer 3.0版本，增强应用生命周期管理解决方案能力，虽受外汇波动和销售环境挑战影响下调销售预期，但通过创新与战略合作有望提升竞争力 [1][4][8] 产品发布 - PTC正式推出Codebeamer 3.0，旨在帮助公司加速产品开发、提高可持续性、确保更高质量和保持监管合规 [1] - Codebeamer 3.0引入现代分支方法和扩展工作集，增强工程团队协作，允许团队跨产品和变体重用需求和测试用例，减少冗余工作和错误 [2] - 新版本包含可持续性模板，支持环保产品开发，减少对物理原型依赖，帮助团队遵循可持续设计最佳实践 [3] - 针对汽车、航空航天和国防、医疗技术等严格监管行业，Codebeamer 3.0提供产品和产品线的全可追溯性，有助于质量保证和合规 [3] 战略合作 - 2024年12月，PTC与微软和大众集团合作设计Codebeamer Copilot，以简化产品需求管理、测试、验证和发布流程，提升实体产品软件开发 [4] - 2024年9月，公司与亚马逊网络服务签署战略合作协议，以扩展Onshape解决方案，增强其功能、提高客户采用率和推进人工智能工作 [7] 业务拓展 - 2022年5月，PTC以约2.8亿美元收购Intland Software，其Codebeamer ALM软件套件将扩大PTC在汽车、生命科学、消费电子和航空航天等安全关键行业的应用生命周期管理业务 [5] 创新展示 - PTC将在2025年汉诺威工业博览会上展示Windchill AI、Codebeamer AI和ServiceMax AI，加强其在人工智能驱动的产品生命周期管理领域的地位 [6] 销售预期 - 受外汇波动和销售环境挑战影响，PTC将2025年销售预期从25.05 - 26.05亿美元下调至24.3 - 25.3亿美元 [8] 股票表现 - PTC目前Zacks排名为3（持有），过去一年股价下跌15.4%，而Zacks计算机软件行业下跌4% [9] 其他推荐股票 - ACI Worldwide Zacks排名为1（强力买入），过去四个季度盈利均超Zacks共识预期，平均惊喜为161.34%，过去一年股价飙升66.2% [10][11] - Unity Software Zacks排名为2（买入），过去四个季度盈利均超Zacks共识预期，平均惊喜为65.52%，长期盈利增长率为5.7%，过去一年股价下跌17.3% [10][12] - Iridium Communications Zacks排名为2（买入），过去四个季度盈利均超Zacks共识预期，平均惊喜为35.22%，过去一年股价上涨12.7% [10][13]

文章核心观点 - 欧洲委员会采纳欧洲药品管理局人用药品委员会对Translarna™（ataluren）不续签授权的意见，该药物在欧洲经济区的有条件营销授权被撤销，但欧盟成员国可依据相关条款允许其继续使用，公司对此失望并期待在各国继续提供药物 [1][2] 公司相关 - PTC是一家全球生物制药公司，专注于为罕见病患者研发、开发和商业化临床差异化药物，通过全球商业化产品推动对变革性药物的投资，以满足患者未满足的医疗需求 [5] - 投资者联系人为Ellen Cavaleri，电话+1 (615) 618-6228，邮箱[email protected]；媒体联系人为Jeanine Clemente，电话+1 (908) 912-9406，邮箱[email protected] [6] 产品相关 - Translarna（ataluren）由PTC发现和开发，是一种蛋白质恢复疗法，用于治疗无义突变杜氏肌营养不良症，在美国是一种研究性新药，已在多个国家获得许可用于治疗2岁及以上可步行患者 [3] 疾病相关 - 杜氏肌营养不良症主要影响男性，是一种罕见的致命遗传病，因缺乏功能性肌营养不良蛋白导致进行性肌肉无力，患者可能在10岁左右失去行走能力，随后出现危及生命的肺部和心脏并发症，通常在25岁左右过早死亡 [4]